A Clinical Trial Assessing the Safety and Effectiveness of the DurAVR® THV System
A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 1650 participants.
Also called NCT07194265
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Not applicable
- Enrolled
- 1,650 participants
- Sponsor
- Anteris Technologies Ltd.
- Registry
-
NCT07194265
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Denmark
- Registry status
- Recruiting
Technical summary
Registry record NCT07194265. Randomized; single masking; primary purpose treatment. Start 2025-10-21 (actual); primary completion 2027-12 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Clinical Trial Assessing the Safety and Effectiveness of the DurAVR® THV System
- Acronym
- PARADIGM
- Condition
- Severe Aortic Stenosis
- Condition
- Valve-in-valve Procedures
- Intervention (Device)
- TAVR (transcatheter aortic valve replacement) with DurAVR® THV
- Intervention (Device)
- TAVR with SAPIEN THV series or the Evolut THV series
- Lead sponsor
- Anteris Technologies Ltd.
Record details
- Record id
cardio:ct-nct07194265- Content hash
527fa9dfe4a48d4162c9a139c0d2402bcad55e8e4b4b7b6b8328df642865e247